X

Week in Review: The Latest from PhRMA

Priscilla VanderVeer
Priscilla VanderVeer September 25, 2015

Week in Review: The Latest from PhRMA.

Share This

week-in-reviewProtecting Innovation: The current marketplace for prescription medicines helps keep spending in check and continued innovation for patients possible. A recent proposal by Presidential Candidate and former Secretary of State Hillary Clinton to regulate drug prices would have a myriad of consequences, including restricted access to medicines for patients, fewer innovative treatments, loss of the nation’s standing as a biomedical world leader and loss of countless jobs. Read more about the implications of the proposal here.

Americans Believe Medicines are Critical to Patient Health: A new poll from PhRMA and Morning Consult revealed that the majority of voters oppose allowing the federal government to set the price of prescription medicines and the vast majority of Americans believe prescription medicines help patients live longer, healthier lives. Find out more here.

Eliminating Hep C Could Reduce Future Spending: Take a look at Milliman’s new report that shows how eliminating hepatitis C today could reduce future U.S. health care spending by $115 billion over the next decade.

Real World Evidence: Tom Hubbard, vice president of policy research at the Network for Excellence in Health Innovation, highlights real world evidence and what it can mean for new therapy options for patients in this guest post.

340B Spotlight: The latest 340B Spotlight post discusses the rise in health care costs stemming from an increase in 340B hospital acquisitions of physician practices. Learn more about how patients and payers are impacted.

National Drug Take Back Day: Saturday, Sept. 26 is National Drug Take Back Day. Mark your calendars for an opportunity to safely dispose of expired, unused or unwanted medications. Check it out here.

Medicare Monday: Did you know that 81% of all Medicare expenditures go toward hospital care and physician care? See this week’s post for a breakdown of Medicare spending. 

Topics: Research and Development, 340B, Hepatitis C